GOLDEN, Colo. — March 9, 2021 — PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis® Needle-free Injection System in polio eradication campaigns. The latest country addition, Somalia, adds to the already successful vaccination programs in Pakistan, Cuba, The Gambia and others. This brings the total number of children with planned or completed polio vaccinations using PharmaJet Needle-Free Injection devices to close to 3 million.
While there is no cure for polio, the disease can be prevented through the administration of a simple and effective vaccine. That is why efforts are underway across the globe to rapidly boost immunity levels in children and protect them from polio paralysis. Multinational NGOs and a broad range of long-term supporters have provided funding to help with this initiative.
“We are pleased to be collaborating with NGOs and country Ministries of Health to vaccinate children against polio. Our Needle-free device is designed for mass vaccination campaigns and routine use in that it delivers a consistent and accurate intradermal vaccination, while being easy-to-use,” commented Chris Cappello, President and CEO, PharmaJet.
For more information about PharmaJet visit pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
PharmaJet’s mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market. The PharmaJet Needle-free Systems are safe, fast, and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit pharmajet.com.